Allena Pharmaceuticals to Present at the 2016 Jefferies Healthcare Conference

NEWTON, Mass.–(BUSINESS WIRE)– Allena Pharmaceuticals, a specialty biopharmaceutical company focused on
developing and commercializing non-systemic protein therapeutics to
treat metabolic and orphan diseases, announced today that Alexey
Margolin, Ph.D., president and chief executive officer of Allena, will
provide a corporate presentation at the 2016 Jefferies Healthcare
Conference at 10:30 a.m. ET, on Tuesday, June 7, 2016, in Ballroom 6 of
the Grand Hyatt, New York, NY.

About Allena Pharmaceuticals

Allena Pharmaceuticals, Inc. is a specialty biopharmaceutical company
focused on developing and commercializing non-systemic protein
therapeutics to treat metabolic and orphan diseases. Allena is currently
conducting two Phase 2 clinical trials of its lead product candidate,
ALLN-177, in patients with hyperoxaluria. The company’s technological
approach enables the design and development of oral protein therapies
that remain in the gastrointestinal (GI) tract, where the protein exerts
its therapeutic effect by degrading toxic metabolites, without being
absorbed into the bloodstream. Led by a proven management team with deep
expertise in protein therapeutic design and development, Allena is
committed to bringing breakthrough new treatments to patients with unmet
medical needs. Based in Newton, MA, the company is supported by a
top-tier investor syndicate including Frazier Healthcare, Third Rock
Ventures, Bessemer Venture Partners, HBM Partners, Pharmstandard
International S.A., Partner Fund Management, Fidelity Management &
Research Company, and other investors. For more information, please
visit www.allenapharma.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160602005986/en/